top of page
Search

Executive Buying Newsletter April 2, 2023

  • Apr 2, 2023
  • 1 min read

We are holding Apple Inc. (Symbol: AAPL) NVDIA Corp (Symbol: NVDA) SPDR Gold Shares (SYMBOL: GLD) and Microsoft Corp (SYMBOL: MSFT) from our previous update. We are removing Hershey Co (SYMBOL: HSY) Lockheed Martin Corp (Symbol: LMT) and ProShares Short S&P500 (SYMBOL: SH).


This is a summary of our performance since our last update:




We are adding 4 additional positions this week. We are adding Meta Platforms (SYMBOL: META) the closing price on March 31, 2023 was $211.94




We are adding Invesco QQQ Trust (SYMBOL: QQQ) the closing price on March 31, 2023 was $320.93




We are adding iShares Silver Trust (SYMBOL:SLV) the closing price on March 31, 2023 was $22.12





Lastly, we are adding iSHares 20+ Treasury Bond ETF (SYMBOL: TLT) the closing price on March 31, 2023 was $106.37






Thank you for putting your trust and time into my ability to create a model that will hopefully add value to all of us. I've started this journey in 2000 as a Nasdaq Market Maker. I also worked as a Proprietary trader, Financial Advisor and currently I manage a hedge fund. I have learned many lessons throughout my career and still continue to learn to this day. I look forward to sharing my experiences with you via this newsletter.


Thank you,


Dominick Manaro



 
 
 

Recent Posts

See All
Executive Buying Newsletter August 3, 2026

Please see the updated list: AMGN (Amgen Inc.) Amgen has delivered solid results with Q1 earnings that beat expectations and raised full-year guidance, supported by steady demand for key products. Sha

 
 
 
Executive Buying Newsletter July 15, 2026

Mid-July 2026 Edition This market has been very choppy since mid-May. It looks like it will break out of this consolidation area one way or another very soon. Here are the list of companies on our new

 
 
 
Executive Buying Newsletter July 3, 2026

Please review the following additions to the newsletter: AMGN (Amgen Inc.) Amgen continues to demonstrate resilience in the biotech sector with solid financial performance. In Q1 2026, the company rep

 
 
 

Comments


bottom of page